Next-generation drug from Eli Lilly boosts weight loss to 24 ...
Jun 26, 2023 · An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss seen...
Drugmakers are racing to find the next Wegovy. These obesity …
Oct 15, 2024 · An obesity pill Novo has advanced an oral version of Wegovy and Lilly has pushed its pill oforglipron into phase 3 trials. But there are many rivals staking their competitive future on the idea that people with obesity will prefer a pill over a shot.
Obesity Pill Data Signal Competition, Hit Drugmaker Shares
Nov 4, 2024 · Lilly is in advanced clinical trials for its oral drug, orforglipron, which produced an average loss of about 15% of body weight in 36 weeks when given daily at the highest dose to adults with ...
FDA approves Zepbound, new Wegovy rival : Shots - Health News : NPR
Nov 8, 2023 · An obesity drug called Zepbound won approval for use in adults from the Food and Drug Administration Wednesday, ushering in a new rival to Novo Nordisk's blockbuster Wegovy.
F.D.A. Approves New Obesity Drug That Will Compete ...
Nov 8, 2023 · The Food and Drug Administration on Wednesday approved an obesity drug from the company Eli Lilly that will be a direct competitor to the wildly popular Wegovy.
Weight loss drug Zepbound is now available, Eli Lilly says
Dec 6, 2023 · CNN — Drug manufacturer Eli Lilly announced Tuesday that its flagship weight loss medication, Zepbound, is now available for patient use. Tirzepatide, its active ingredient, had been approved...
Pfizer targets obesity with new once-daily danuglipron drug
Jul 11, 2024 · Pfizer announced early Thursday morning that it has selected its preferred once-daily modified release formulation of danuglipron, a move that it said was a significant milestone in the obesity drug’s development.
The Race for the Next Ozempic | WIRED
Jul 24, 2024 · Researchers are now racing to develop new anti-obesity medications that are more effective, more convenient, or produce fewer side effects than the ones currently on the market.
FDA approves Eli Lilly's Zepbound, a weight loss drug ... - NBC News
The Food and Drug Administration on Wednesday approved Zepbound, a new weight loss drug from drugmaker Eli Lilly that was shown in clinical trials to help people lose up to 52 pounds in 16 months.
FDA Approves New Medication for Chronic Weight Management
The FDA approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition, for use in addition to a reduced...